| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Pancreatic Neoplasms | 47 | 2022 | 5061 | 3.130 |
Why?
|
| Carcinoma, Pancreatic Ductal | 18 | 2022 | 1724 | 1.520 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 37 | 2022 | 15862 | 1.420 |
Why?
|
| Colorectal Neoplasms | 21 | 2023 | 3578 | 1.360 |
Why?
|
| Deoxycytidine | 19 | 2021 | 1353 | 1.080 |
Why?
|
| Pancreatectomy | 11 | 2021 | 652 | 0.870 |
Why?
|
| Adenocarcinoma | 21 | 2020 | 7789 | 0.840 |
Why?
|
| Organoplatinum Compounds | 9 | 2020 | 702 | 0.830 |
Why?
|
| Minocycline | 1 | 2020 | 182 | 0.640 |
Why?
|
| Biomarkers, Tumor | 12 | 2019 | 10331 | 0.630 |
Why?
|
| Bevacizumab | 9 | 2022 | 938 | 0.590 |
Why?
|
| Germ-Line Mutation | 2 | 2019 | 1046 | 0.560 |
Why?
|
| Exercise | 4 | 2019 | 1183 | 0.550 |
Why?
|
| Preoperative Care | 8 | 2021 | 1529 | 0.530 |
Why?
|
| Cachexia | 1 | 2017 | 161 | 0.520 |
Why?
|
| Phenylurea Compounds | 1 | 2018 | 580 | 0.510 |
Why?
|
| Aged | 60 | 2022 | 70117 | 0.490 |
Why?
|
| Neoplasm Recurrence, Local | 8 | 2018 | 10035 | 0.480 |
Why?
|
| Fluorouracil | 14 | 2022 | 1944 | 0.470 |
Why?
|
| Aged, 80 and over | 34 | 2021 | 29902 | 0.470 |
Why?
|
| Pancreaticoduodenectomy | 6 | 2017 | 690 | 0.470 |
Why?
|
| Middle Aged | 59 | 2022 | 86204 | 0.450 |
Why?
|
| Albumins | 4 | 2020 | 258 | 0.410 |
Why?
|
| Erlotinib Hydrochloride | 4 | 2018 | 388 | 0.410 |
Why?
|
| Neoadjuvant Therapy | 12 | 2021 | 4975 | 0.410 |
Why?
|
| Neoplasm Staging | 17 | 2021 | 13658 | 0.400 |
Why?
|
| Pyridines | 1 | 2018 | 1244 | 0.400 |
Why?
|
| Patient Reported Outcome Measures | 1 | 2017 | 799 | 0.400 |
Why?
|
| Male | 66 | 2022 | 123000 | 0.390 |
Why?
|
| Peritoneal Neoplasms | 3 | 2019 | 821 | 0.380 |
Why?
|
| Adult | 45 | 2022 | 77950 | 0.380 |
Why?
|
| Cytokines | 2 | 2017 | 2809 | 0.370 |
Why?
|
| BRCA2 Protein | 2 | 2018 | 358 | 0.370 |
Why?
|
| Female | 65 | 2022 | 141928 | 0.360 |
Why?
|
| Pyrazoles | 1 | 2018 | 1471 | 0.350 |
Why?
|
| Tomography, X-Ray Computed | 5 | 2021 | 7551 | 0.350 |
Why?
|
| Molecular Targeted Therapy | 1 | 2019 | 2330 | 0.340 |
Why?
|
| Genetic Predisposition to Disease | 2 | 2019 | 5539 | 0.340 |
Why?
|
| Humans | 80 | 2023 | 261506 | 0.340 |
Why?
|
| Antineoplastic Agents | 11 | 2021 | 14289 | 0.330 |
Why?
|
| Camptothecin | 4 | 2020 | 517 | 0.310 |
Why?
|
| DNA Mismatch Repair | 4 | 2022 | 268 | 0.310 |
Why?
|
| Antibodies, Monoclonal, Humanized | 11 | 2023 | 3251 | 0.310 |
Why?
|
| Inflammation | 2 | 2017 | 2522 | 0.310 |
Why?
|
| Drugs, Investigational | 1 | 2008 | 135 | 0.310 |
Why?
|
| Survival Rate | 18 | 2020 | 12221 | 0.300 |
Why?
|
| Neuroendocrine Tumors | 3 | 2022 | 634 | 0.300 |
Why?
|
| Leucovorin | 7 | 2022 | 332 | 0.300 |
Why?
|
| Exercise Therapy | 3 | 2019 | 288 | 0.300 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2011 | 479 | 0.290 |
Why?
|
| Cognition Disorders | 1 | 2012 | 786 | 0.290 |
Why?
|
| Cetuximab | 3 | 2017 | 472 | 0.280 |
Why?
|
| Liver Neoplasms | 6 | 2019 | 4557 | 0.280 |
Why?
|
| Paclitaxel | 4 | 2020 | 1996 | 0.280 |
Why?
|
| Brain Injuries | 1 | 2012 | 787 | 0.280 |
Why?
|
| Protein Kinase Inhibitors | 3 | 2018 | 4757 | 0.270 |
Why?
|
| Benzamides | 1 | 2011 | 1832 | 0.270 |
Why?
|
| Colonic Neoplasms | 2 | 2023 | 1390 | 0.250 |
Why?
|
| Double-Blind Method | 3 | 2020 | 2588 | 0.250 |
Why?
|
| Treatment Outcome | 22 | 2022 | 32848 | 0.250 |
Why?
|
| Chemoradiotherapy | 6 | 2019 | 1946 | 0.240 |
Why?
|
| Neoplasm Metastasis | 8 | 2019 | 5112 | 0.230 |
Why?
|
| Retrospective Studies | 27 | 2021 | 37905 | 0.230 |
Why?
|
| Kaplan-Meier Estimate | 9 | 2020 | 6207 | 0.230 |
Why?
|
| Hypertension, Portal | 2 | 2017 | 124 | 0.230 |
Why?
|
| Carcinoid Tumor | 2 | 2015 | 280 | 0.220 |
Why?
|
| Survival Analysis | 10 | 2020 | 9180 | 0.220 |
Why?
|
| Prognosis | 16 | 2020 | 21713 | 0.220 |
Why?
|
| BRCA1 Protein | 3 | 2021 | 493 | 0.220 |
Why?
|
| Cancer Survivors | 2 | 2019 | 650 | 0.210 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 2 | 2021 | 1331 | 0.210 |
Why?
|
| Postoperative Care | 3 | 2020 | 739 | 0.210 |
Why?
|
| Intra-Abdominal Fat | 2 | 2019 | 95 | 0.210 |
Why?
|
| Chemotherapy, Adjuvant | 8 | 2020 | 3890 | 0.200 |
Why?
|
| Pyrimidines | 3 | 2020 | 3518 | 0.200 |
Why?
|
| Splenic Infarction | 1 | 2020 | 14 | 0.190 |
Why?
|
| Hypersplenism | 1 | 2020 | 23 | 0.190 |
Why?
|
| Hydrocarbons, Fluorinated | 1 | 2020 | 26 | 0.190 |
Why?
|
| Metastasectomy | 2 | 2020 | 200 | 0.180 |
Why?
|
| Walking | 2 | 2019 | 277 | 0.180 |
Why?
|
| Body Composition | 3 | 2019 | 595 | 0.180 |
Why?
|
| Fanconi Anemia Complementation Group N Protein | 1 | 2019 | 27 | 0.180 |
Why?
|
| Vascular Remodeling | 1 | 2019 | 48 | 0.170 |
Why?
|
| Antimetabolites, Antineoplastic | 3 | 2020 | 1299 | 0.170 |
Why?
|
| Follow-Up Studies | 13 | 2021 | 14889 | 0.170 |
Why?
|
| Phthalazines | 1 | 2021 | 253 | 0.170 |
Why?
|
| Clinical Trials, Phase II as Topic | 3 | 2023 | 665 | 0.170 |
Why?
|
| Capecitabine | 4 | 2016 | 388 | 0.170 |
Why?
|
| Aspirin | 1 | 2022 | 455 | 0.170 |
Why?
|
| Absorptiometry, Photon | 1 | 2019 | 239 | 0.170 |
Why?
|
| Prodrugs | 1 | 2020 | 217 | 0.160 |
Why?
|
| Disease-Free Survival | 12 | 2020 | 10001 | 0.160 |
Why?
|
| Mutation | 6 | 2021 | 15179 | 0.160 |
Why?
|
| Combined Modality Therapy | 7 | 2020 | 8865 | 0.160 |
Why?
|
| Proto-Oncogene Proteins B-raf | 2 | 2016 | 1283 | 0.160 |
Why?
|
| Physical Conditioning, Animal | 1 | 2019 | 112 | 0.160 |
Why?
|
| Ribonuclease, Pancreatic | 1 | 2018 | 53 | 0.160 |
Why?
|
| Receptors, Somatomedin | 1 | 2018 | 70 | 0.160 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2019 | 170 | 0.160 |
Why?
|
| Janus Kinase 1 | 1 | 2018 | 121 | 0.150 |
Why?
|
| Gastrointestinal Neoplasms | 2 | 2020 | 600 | 0.150 |
Why?
|
| F-Box-WD Repeat-Containing Protein 7 | 1 | 2017 | 83 | 0.150 |
Why?
|
| Bacterial Infections | 1 | 2021 | 479 | 0.150 |
Why?
|
| Cell-Free Nucleic Acids | 1 | 2019 | 224 | 0.150 |
Why?
|
| Fatigue | 2 | 2022 | 1239 | 0.150 |
Why?
|
| Sarcopenia | 2 | 2017 | 110 | 0.150 |
Why?
|
| Frailty | 1 | 2019 | 113 | 0.150 |
Why?
|
| Esophageal and Gastric Varices | 1 | 2017 | 85 | 0.150 |
Why?
|
| Ascites | 1 | 2017 | 198 | 0.150 |
Why?
|
| Home Care Services | 1 | 2017 | 92 | 0.140 |
Why?
|
| Sulfonamides | 2 | 2016 | 1823 | 0.140 |
Why?
|
| Gene Frequency | 1 | 2019 | 1163 | 0.140 |
Why?
|
| Patient Compliance | 2 | 2019 | 667 | 0.140 |
Why?
|
| Lung Neoplasms | 4 | 2019 | 11538 | 0.140 |
Why?
|
| Social Support | 1 | 2019 | 560 | 0.140 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2018 | 221 | 0.140 |
Why?
|
| Paresthesia | 1 | 2016 | 33 | 0.140 |
Why?
|
| Pancreatic Fistula | 1 | 2016 | 99 | 0.140 |
Why?
|
| Common Bile Duct Neoplasms | 1 | 2017 | 145 | 0.140 |
Why?
|
| Ampulla of Vater | 1 | 2017 | 155 | 0.140 |
Why?
|
| Touch | 1 | 2016 | 71 | 0.130 |
Why?
|
| Vimentin | 1 | 2016 | 253 | 0.130 |
Why?
|
| Carcinoma, Mucoepidermoid | 1 | 2016 | 137 | 0.130 |
Why?
|
| Parenteral Nutrition, Total | 1 | 2015 | 140 | 0.130 |
Why?
|
| Embolization, Therapeutic | 1 | 2020 | 551 | 0.130 |
Why?
|
| Somatostatin | 1 | 2015 | 114 | 0.130 |
Why?
|
| Recovery of Function | 1 | 2019 | 703 | 0.130 |
Why?
|
| Perfusion Imaging | 1 | 2015 | 30 | 0.130 |
Why?
|
| Digestive System Neoplasms | 1 | 2015 | 82 | 0.130 |
Why?
|
| Octreotide | 1 | 2015 | 118 | 0.130 |
Why?
|
| Chemoradiotherapy, Adjuvant | 2 | 2016 | 565 | 0.130 |
Why?
|
| Cohort Studies | 4 | 2020 | 9244 | 0.120 |
Why?
|
| Family Health | 1 | 2015 | 325 | 0.120 |
Why?
|
| Janus Kinase 2 | 1 | 2018 | 679 | 0.120 |
Why?
|
| src-Family Kinases | 1 | 2017 | 478 | 0.120 |
Why?
|
| Microsatellite Instability | 3 | 2022 | 400 | 0.120 |
Why?
|
| Prospective Studies | 9 | 2022 | 12873 | 0.120 |
Why?
|
| Nitriles | 1 | 2018 | 906 | 0.120 |
Why?
|
| Multidetector Computed Tomography | 1 | 2015 | 150 | 0.120 |
Why?
|
| CA-19-9 Antigen | 3 | 2020 | 144 | 0.120 |
Why?
|
| ErbB Receptors | 3 | 2018 | 2295 | 0.120 |
Why?
|
| Intestinal Obstruction | 1 | 2015 | 202 | 0.110 |
Why?
|
| Serum Albumin | 1 | 2014 | 257 | 0.110 |
Why?
|
| High-Throughput Nucleotide Sequencing | 2 | 2019 | 2291 | 0.110 |
Why?
|
| Dasatinib | 1 | 2017 | 862 | 0.110 |
Why?
|
| Treatment Failure | 2 | 2019 | 1391 | 0.110 |
Why?
|
| Maximum Tolerated Dose | 3 | 2018 | 1290 | 0.110 |
Why?
|
| Gastrointestinal Microbiome | 1 | 2021 | 907 | 0.110 |
Why?
|
| Angiogenesis Inhibitors | 2 | 2016 | 1248 | 0.100 |
Why?
|
| Sequence Analysis, DNA | 1 | 2019 | 2483 | 0.100 |
Why?
|
| Mutation, Missense | 1 | 2017 | 1152 | 0.100 |
Why?
|
| Cisplatin | 3 | 2014 | 2432 | 0.100 |
Why?
|
| Pain | 1 | 2020 | 1658 | 0.100 |
Why?
|
| Leukopenia | 1 | 2011 | 151 | 0.100 |
Why?
|
| Drug Administration Schedule | 4 | 2020 | 3472 | 0.100 |
Why?
|
| Quinazolines | 2 | 2013 | 923 | 0.100 |
Why?
|
| Indoles | 1 | 2016 | 1009 | 0.100 |
Why?
|
| Young Adult | 8 | 2021 | 21445 | 0.090 |
Why?
|
| Poly (ADP-Ribose) Polymerase-1 | 1 | 2011 | 170 | 0.090 |
Why?
|
| Taxoids | 2 | 2011 | 967 | 0.090 |
Why?
|
| Recurrence | 1 | 2018 | 4758 | 0.090 |
Why?
|
| Drug Resistance, Neoplasm | 3 | 2018 | 5178 | 0.090 |
Why?
|
| Antibodies, Monoclonal | 3 | 2018 | 4367 | 0.090 |
Why?
|
| Medical Oncology | 1 | 2018 | 1423 | 0.080 |
Why?
|
| DNA | 1 | 2017 | 2693 | 0.080 |
Why?
|
| Time Factors | 6 | 2021 | 12926 | 0.080 |
Why?
|
| Anti-Bacterial Agents | 1 | 2021 | 2992 | 0.080 |
Why?
|
| Genomics | 1 | 2019 | 2738 | 0.080 |
Why?
|
| Neoplasms | 3 | 2020 | 15193 | 0.080 |
Why?
|
| Preoperative Period | 2 | 2020 | 344 | 0.080 |
Why?
|
| Duodenal Neoplasms | 1 | 2008 | 138 | 0.080 |
Why?
|
| Obesity | 2 | 2022 | 2884 | 0.080 |
Why?
|
| Hypertension | 1 | 2016 | 1503 | 0.070 |
Why?
|
| Quality of Life | 2 | 2019 | 4532 | 0.070 |
Why?
|
| Intestinal Neoplasms | 1 | 2008 | 189 | 0.070 |
Why?
|
| Breast Neoplasms | 1 | 2011 | 15694 | 0.070 |
Why?
|
| Multivariate Analysis | 3 | 2021 | 4298 | 0.070 |
Why?
|
| Palliative Care | 1 | 2018 | 2037 | 0.070 |
Why?
|
| Gene Expression Regulation, Neoplastic | 2 | 2019 | 8873 | 0.070 |
Why?
|
| Up-Regulation | 1 | 2012 | 2450 | 0.070 |
Why?
|
| Thrombocytopenia | 1 | 2011 | 846 | 0.070 |
Why?
|
| Drug Substitution | 2 | 2016 | 87 | 0.070 |
Why?
|
| Anemia | 1 | 2011 | 689 | 0.070 |
Why?
|
| Adolescent | 7 | 2022 | 31252 | 0.070 |
Why?
|
| Intestine, Small | 1 | 2008 | 499 | 0.060 |
Why?
|
| Predictive Value of Tests | 3 | 2021 | 4892 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-kit | 1 | 2006 | 479 | 0.060 |
Why?
|
| Self Report | 2 | 2019 | 756 | 0.060 |
Why?
|
| Cell Differentiation | 1 | 2015 | 4078 | 0.060 |
Why?
|
| Carcinoma, Small Cell | 1 | 2006 | 408 | 0.060 |
Why?
|
| TOR Serine-Threonine Kinases | 1 | 2010 | 1546 | 0.060 |
Why?
|
| Animals | 5 | 2019 | 59536 | 0.050 |
Why?
|
| United States | 2 | 2022 | 15433 | 0.050 |
Why?
|
| Lymphatic Metastasis | 3 | 2017 | 4844 | 0.050 |
Why?
|
| Body Mass Index | 2 | 2022 | 2203 | 0.050 |
Why?
|
| Depression | 1 | 2012 | 1715 | 0.050 |
Why?
|
| Hospitalization | 1 | 2011 | 2083 | 0.050 |
Why?
|
| Proportional Hazards Models | 3 | 2015 | 4988 | 0.050 |
Why?
|
| Hepatectomy | 1 | 2008 | 1011 | 0.050 |
Why?
|
| Neuroectodermal Tumors, Primitive | 1 | 2022 | 100 | 0.050 |
Why?
|
| Clinical Trials, Phase I as Topic | 1 | 2004 | 604 | 0.050 |
Why?
|
| Postoperative Complications | 1 | 2016 | 5542 | 0.050 |
Why?
|
| Epidemiologic Methods | 1 | 2021 | 254 | 0.050 |
Why?
|
| Microsatellite Repeats | 1 | 2022 | 575 | 0.050 |
Why?
|
| Receptors, Androgen | 1 | 2006 | 878 | 0.050 |
Why?
|
| Everolimus | 2 | 2015 | 415 | 0.050 |
Why?
|
| Odds Ratio | 2 | 2015 | 2316 | 0.050 |
Why?
|
| Food-Drug Interactions | 1 | 2020 | 22 | 0.050 |
Why?
|
| Skin Neoplasms | 1 | 2016 | 4654 | 0.050 |
Why?
|
| Liver | 1 | 2009 | 2961 | 0.040 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2019 | 3821 | 0.040 |
Why?
|
| Prevalence | 2 | 2018 | 3260 | 0.040 |
Why?
|
| Tumor Burden | 2 | 2015 | 1987 | 0.040 |
Why?
|
| Platelet Count | 1 | 2020 | 490 | 0.040 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2006 | 882 | 0.040 |
Why?
|
| Brain | 1 | 2012 | 4113 | 0.040 |
Why?
|
| Physical Fitness | 1 | 2019 | 122 | 0.040 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2004 | 2231 | 0.040 |
Why?
|
| Germ Cells | 1 | 2021 | 335 | 0.040 |
Why?
|
| Hand Strength | 1 | 2019 | 65 | 0.040 |
Why?
|
| Neoplasm Invasiveness | 2 | 2017 | 3981 | 0.040 |
Why?
|
| Signal Transduction | 3 | 2018 | 11965 | 0.040 |
Why?
|
| Age Factors | 2 | 2018 | 5377 | 0.040 |
Why?
|
| Area Under Curve | 1 | 2020 | 700 | 0.040 |
Why?
|
| Diarrhea | 1 | 2022 | 686 | 0.040 |
Why?
|
| Spleen | 1 | 2020 | 676 | 0.040 |
Why?
|
| Medical History Taking | 1 | 2018 | 173 | 0.040 |
Why?
|
| DNA Methylation | 2 | 2019 | 2669 | 0.040 |
Why?
|
| Cost-Benefit Analysis | 1 | 2022 | 945 | 0.040 |
Why?
|
| Lymphocytes, Tumor-Infiltrating | 1 | 2022 | 992 | 0.040 |
Why?
|
| Subcutaneous Fat | 1 | 2017 | 92 | 0.040 |
Why?
|
| Anthropometry | 1 | 2017 | 269 | 0.040 |
Why?
|
| Texas | 2 | 2020 | 6311 | 0.040 |
Why?
|
| Residence Characteristics | 1 | 2019 | 348 | 0.040 |
Why?
|
| Radiotherapy Dosage | 1 | 2004 | 3842 | 0.040 |
Why?
|
| Clinical Decision-Making | 1 | 2020 | 524 | 0.040 |
Why?
|
| Cattle | 1 | 2018 | 783 | 0.040 |
Why?
|
| Age of Onset | 1 | 2018 | 827 | 0.040 |
Why?
|
| Motivation | 1 | 2019 | 499 | 0.030 |
Why?
|
| Genetic Counseling | 1 | 2018 | 380 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 2018 | 347 | 0.030 |
Why?
|
| Receptors, Antigen, T-Cell | 1 | 2022 | 1146 | 0.030 |
Why?
|
| Radiography | 1 | 2020 | 1904 | 0.030 |
Why?
|
| Biomarkers | 2 | 2018 | 5047 | 0.030 |
Why?
|
| Child | 4 | 2020 | 29154 | 0.030 |
Why?
|
| Vascular Endothelial Growth Factor A | 1 | 2022 | 1533 | 0.030 |
Why?
|
| Single-Blind Method | 1 | 2016 | 409 | 0.030 |
Why?
|
| Radiation-Sensitizing Agents | 1 | 2017 | 363 | 0.030 |
Why?
|
| Portal Vein | 1 | 2017 | 355 | 0.030 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2020 | 852 | 0.030 |
Why?
|
| Delayed-Action Preparations | 1 | 2015 | 208 | 0.030 |
Why?
|
| Hospice Care | 1 | 2016 | 156 | 0.030 |
Why?
|
| Health Behavior | 1 | 2019 | 603 | 0.030 |
Why?
|
| Neoplasm Transplantation | 1 | 2018 | 1519 | 0.030 |
Why?
|
| Postoperative Period | 1 | 2016 | 665 | 0.030 |
Why?
|
| HeLa Cells | 1 | 2018 | 1643 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2016 | 829 | 0.030 |
Why?
|
| CpG Islands | 1 | 2016 | 633 | 0.030 |
Why?
|
| Binding Sites | 1 | 2018 | 2171 | 0.030 |
Why?
|
| Blood Flow Velocity | 1 | 2015 | 475 | 0.030 |
Why?
|
| Indazoles | 1 | 2015 | 297 | 0.030 |
Why?
|
| Induction Chemotherapy | 1 | 2016 | 669 | 0.030 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 1 | 2015 | 355 | 0.030 |
Why?
|
| DNA Damage | 1 | 2021 | 1954 | 0.030 |
Why?
|
| Mice | 3 | 2019 | 34495 | 0.030 |
Why?
|
| Cross-Sectional Studies | 1 | 2022 | 4314 | 0.030 |
Why?
|
| Quality of Health Care | 1 | 2017 | 621 | 0.030 |
Why?
|
| Comorbidity | 1 | 2019 | 2352 | 0.030 |
Why?
|
| DNA Mutational Analysis | 1 | 2018 | 2283 | 0.030 |
Why?
|
| Patient Selection | 1 | 2020 | 2055 | 0.030 |
Why?
|
| Longitudinal Studies | 1 | 2017 | 1945 | 0.030 |
Why?
|
| Patient Readmission | 1 | 2016 | 548 | 0.030 |
Why?
|
| Piperazines | 1 | 2021 | 2101 | 0.030 |
Why?
|
| Cell Line, Tumor | 2 | 2018 | 14551 | 0.030 |
Why?
|
| Patient Satisfaction | 1 | 2017 | 915 | 0.030 |
Why?
|
| Stents | 1 | 2017 | 1096 | 0.020 |
Why?
|
| Antigens, Neoplasm | 1 | 2017 | 1506 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2017 | 2803 | 0.020 |
Why?
|
| Sex Factors | 1 | 2016 | 2139 | 0.020 |
Why?
|
| Azacitidine | 1 | 2016 | 1149 | 0.020 |
Why?
|
| Muscle, Skeletal | 1 | 2017 | 1270 | 0.020 |
Why?
|
| Risk Factors | 2 | 2018 | 17523 | 0.020 |
Why?
|
| Body Weight | 1 | 2014 | 1293 | 0.020 |
Why?
|
| Biopsy | 1 | 2016 | 3443 | 0.020 |
Why?
|
| Platinum Compounds | 1 | 2008 | 131 | 0.020 |
Why?
|
| Hospital Mortality | 1 | 2014 | 1274 | 0.020 |
Why?
|
| Logistic Models | 1 | 2015 | 3441 | 0.020 |
Why?
|
| Immunoenzyme Techniques | 1 | 2010 | 1165 | 0.020 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2010 | 1062 | 0.020 |
Why?
|
| Retreatment | 1 | 2008 | 452 | 0.020 |
Why?
|
| Surveys and Questionnaires | 1 | 2019 | 5687 | 0.020 |
Why?
|
| Disease Models, Animal | 1 | 2019 | 7222 | 0.020 |
Why?
|
| Sirolimus | 1 | 2010 | 814 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2018 | 5159 | 0.020 |
Why?
|
| Hematologic Diseases | 1 | 2007 | 242 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2016 | 6869 | 0.010 |
Why?
|
| Immunosuppressive Agents | 1 | 2010 | 1375 | 0.010 |
Why?
|
| Drug Synergism | 1 | 2007 | 1313 | 0.010 |
Why?
|
| Disease Progression | 1 | 2015 | 6682 | 0.010 |
Why?
|
| Proto-Oncogene Proteins c-akt | 1 | 2010 | 2054 | 0.010 |
Why?
|
| Phosphorylation | 1 | 2010 | 4804 | 0.010 |
Why?
|
| Receptor, ErbB-2 | 1 | 2006 | 2518 | 0.010 |
Why?
|
| Immunohistochemistry | 1 | 2006 | 7548 | 0.010 |
Why?
|
| Apoptosis | 1 | 2007 | 7591 | 0.010 |
Why?
|
| Infant | 1 | 2006 | 13310 | 0.010 |
Why?
|
| Child, Preschool | 1 | 2006 | 16273 | 0.010 |
Why?
|